Switch to:
Also traded in: Germany, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.38
NAS:ALXN's Cash to Debt is ranked lower than
88% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: 46.43 vs. NAS:ALXN: 0.38 )
Ranked among companies with meaningful Cash to Debt only.
NAS:ALXN' s Cash to Debt Range Over the Past 10 Years
Min: 0.3  Med: 2.79 Max: No Debt
Current: 0.38
Equity to Asset 0.64
NAS:ALXN's Equity to Asset is ranked lower than
54% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. NAS:ALXN: 0.64 )
Ranked among companies with meaningful Equity to Asset only.
NAS:ALXN' s Equity to Asset Range Over the Past 10 Years
Min: 0.04  Med: 0.65 Max: 0.95
Current: 0.64
0.04
0.95
Interest Coverage 6.66
NAS:ALXN's Interest Coverage is ranked lower than
88% of the 458 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. NAS:ALXN: 6.66 )
Ranked among companies with meaningful Interest Coverage only.
NAS:ALXN' s Interest Coverage Range Over the Past 10 Years
Min: 6.66  Med: 136.04 Max: 292.93
Current: 6.66
6.66
292.93
F-Score: 6
Z-Score: 3.99
M-Score: -2.36
WACC vs ROIC
10.38%
4.11%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 21.57
NAS:ALXN's Operating margin (%) is ranked higher than
88% of the 749 Companies
in the Global Biotechnology industry.

( Industry Median: -78.20 vs. NAS:ALXN: 21.57 )
Ranked among companies with meaningful Operating margin (%) only.
NAS:ALXN' s Operating margin (%) Range Over the Past 10 Years
Min: -8798.78  Med: 25.18 Max: 38.89
Current: 21.57
-8798.78
38.89
Net-margin (%) 12.46
NAS:ALXN's Net-margin (%) is ranked higher than
84% of the 749 Companies
in the Global Biotechnology industry.

( Industry Median: -75.28 vs. NAS:ALXN: 12.46 )
Ranked among companies with meaningful Net-margin (%) only.
NAS:ALXN' s Net-margin (%) Range Over the Past 10 Years
Min: -8441.21  Med: 17.12 Max: 76.31
Current: 12.46
-8441.21
76.31
ROE (%) 4.46
NAS:ALXN's ROE (%) is ranked higher than
80% of the 878 Companies
in the Global Biotechnology industry.

( Industry Median: -33.45 vs. NAS:ALXN: 4.46 )
Ranked among companies with meaningful ROE (%) only.
NAS:ALXN' s ROE (%) Range Over the Past 10 Years
Min: -136.75  Med: 14.48 Max: 63.11
Current: 4.46
-136.75
63.11
ROA (%) 2.81
NAS:ALXN's ROA (%) is ranked higher than
82% of the 971 Companies
in the Global Biotechnology industry.

( Industry Median: -29.51 vs. NAS:ALXN: 2.81 )
Ranked among companies with meaningful ROA (%) only.
NAS:ALXN' s ROA (%) Range Over the Past 10 Years
Min: -45.22  Med: 9.66 Max: 46.71
Current: 2.81
-45.22
46.71
ROC (Joel Greenblatt) (%) 49.74
NAS:ALXN's ROC (Joel Greenblatt) (%) is ranked higher than
91% of the 931 Companies
in the Global Biotechnology industry.

( Industry Median: -372.06 vs. NAS:ALXN: 49.74 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NAS:ALXN' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -509.26  Med: 54.85 Max: 173.86
Current: 49.74
-509.26
173.86
Revenue Growth (3Y)(%) 28.30
NAS:ALXN's Revenue Growth (3Y)(%) is ranked higher than
79% of the 482 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. NAS:ALXN: 28.30 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NAS:ALXN' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -68.5  Med: 38.8 Max: 462.4
Current: 28.3
-68.5
462.4
EBITDA Growth (3Y)(%) 15.20
NAS:ALXN's EBITDA Growth (3Y)(%) is ranked higher than
68% of the 521 Companies
in the Global Biotechnology industry.

( Industry Median: 1.50 vs. NAS:ALXN: 15.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NAS:ALXN' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -10.7  Med: 22.1 Max: 73.2
Current: 15.2
-10.7
73.2
EPS Growth (3Y)(%) -19.40
NAS:ALXN's EPS Growth (3Y)(%) is ranked lower than
67% of the 511 Companies
in the Global Biotechnology industry.

( Industry Median: -4.20 vs. NAS:ALXN: -19.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NAS:ALXN' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -19.4  Med: 11.05 Max: 76.4
Current: -19.4
-19.4
76.4
» NAS:ALXN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

ALXN Guru Trades in Q4 2015

Louis Moore Bacon 30,000 sh (New)
Ron Baron 61,177 sh (+87.52%)
Pioneer Investments 41,785 sh (+30.33%)
David Carlson 160,000 sh (unchged)
Samuel Isaly 223,000 sh (unchged)
Jim Simons Sold Out
Frank Sands 6,056,762 sh (-5.06%)
» More
Q1 2016

ALXN Guru Trades in Q1 2016

Joel Greenblatt 10,684 sh (New)
Steven Cohen 85,700 sh (New)
John Paulson 157,200 sh (New)
Dodge & Cox 1,820 sh (New)
David Carlson 160,000 sh (unchged)
Samuel Isaly 223,000 sh (unchged)
Louis Moore Bacon Sold Out
Pioneer Investments 41,290 sh (-1.18%)
Ron Baron 55,950 sh (-8.54%)
Frank Sands 5,211,879 sh (-13.95%)
» More
Q2 2016

ALXN Guru Trades in Q2 2016

Manning & Napier Advisors, Inc 95,050 sh (New)
Paul Tudor Jones 13,329 sh (New)
Steven Cohen 529,500 sh (+517.85%)
Joel Greenblatt 58,459 sh (+447.16%)
John Paulson 268,000 sh (+70.48%)
David Carlson 190,000 sh (+18.75%)
Ron Baron 62,249 sh (+11.26%)
Pioneer Investments 41,387 sh (+0.23%)
Samuel Isaly 396,700 sh (+77.89%)
Dodge & Cox Sold Out
Frank Sands 4,874,758 sh (-6.47%)
» More
Q3 2016

ALXN Guru Trades in Q3 2016

Paul Tudor Jones 153,511 sh (+1051.71%)
Steven Cohen 611,500 sh (+15.49%)
Manning & Napier Advisors, Inc 106,610 sh (+12.16%)
Frank Sands 5,245,752 sh (+7.61%)
David Carlson 190,000 sh (unchged)
Pioneer Investments 40,938 sh (-1.08%)
John Paulson 227,700 sh (-15.04%)
Joel Greenblatt 46,797 sh (-19.95%)
Ron Baron 44,260 sh (-28.90%)
Samuel Isaly 183,684 sh (-53.70%)
» More
» Details

Insider Trades

Latest Guru Trades with ALXN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:VRTX, NAS:INCY, OTCPK:CSLLY, OTCPK:ALIOY, NAS:BMRN, OTCPK:GIKLY, NAS:MDVN, OTCPK:UCBJY, NAS:REGN, OTCPK:GMXAY, OTCPK:NVZMF, NAS:SGEN, NAS:ALKS, NAS:TSRO, NAS:JAZZ, NAS:UTHR, NAS:IONS, NAS:EXEL, NAS:ALNY, NAS:TECH » details
Traded in other countries:AXP.Germany, ALXN.Switzerland, 0QZM.UK,
Alexion Pharmaceuticals Inc is a biopharmaceutical company engaged in serving patients with severe and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.

Alexion Pharmaceuticals Inc is a Delaware based company, incorporated in 1992. The Company is a bio-pharmaceutical company serving patients with severe and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. Its marketed product Soliris (eculizumab) is the first and only therapeutic approved for patients with two ultra-rare and severe disorders resulting from chronic uncontrolled activation of the complement component of the immune system: paroxysmal nocturnal hemoglobinuria, an ultra-rare and life-threatening blood disorder, and atypical hemolytic uremic syndrome, an ultra-rare and life-threatening genetic disease. The Company is also evaluating other potential indications for Soliris in other diseases in which chronic uncontrolled complement activation is the underlying mechanism. It operates in United States, Europe and Asia Pacific. It competes with companies that produce and market synthetic compounds and with specialized biotechnology firms in the United States, Europe and in other countries and regions, as well as a growing number of large pharmaceutical companies that are developing biotechnology products. The preclinical studies and clinical testing, manufacture, labeling, storage, record keeping, advertising, promotion, export, and marketing, among other things, of products and product candidates, including Soliris, are subject to extensive regulation by governmental authorities in the United States, the European Union and other territories.

Guru Investment Theses on Alexion Pharmaceuticals Inc

Spiros Segalas on Alexion Pharmaceuticals - Aug 18, 2016



Many Health Care stocks that have been strong positive contributors to return over past quarters continued to face concerns about drug pricing. Biotechnology companies that sell innovative, high priced drugs lost ground, including Alexion Pharmaceuticals (NASDAQ:ALXN). We believe that the long-term fundamentals of the Fund’s biotechnology holdings remain intact, and that current valuations underestimate the potential of pipeline drugs.





From Spiros Segamas' Armiel Appreciation second quarter 2016 commentary.



Check out Spiros Segalas latest stock trades

Baron Funds Comments on Alexion Pharmaceuticals - May 23, 2016

Shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) fell in the first quarter as a result of the significant correction in the biotech/pharma space. Alexion develops treatments for rare diseases. Its high foreign exchange exposure and high multiple also pressured the stock. Overall, we believe there have been no significant changes to the fundamentals of Alexion’s investment thesis (innovative, exceptionally well-managed company with unique assets and pricing power) and we retain conviction.



From Baron Fifth Avenue Growth Fund first quarter commentary 2016.



Check out Ron Baron latest stock trades

Baron Funds Comments on Alexion Pharmaceuticals - May 23, 2016

Shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) fell in the first quarter as a result of the significant correction in the biotech/pharma space. Alexion develops treatments for rare diseases. Its high foreign exchange exposure and high



From Baron Fifth Avenue Growth Fund first quarter commentary 2016.



Check out Ron Baron latest stock trades

Baron Funds Comments on Alexion Pharmaceuticals - May 06, 2016

Shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) fell sharply in the first quarter as a result of the massive correction in the biotech/pharma space. Alexion develops treatments for rare diseases. Its high foreign exchange exposure and high multiple also pressured the stock. Overall, we believe there have been no significant changes to the fundamentals of Alexion’s story and we retain conviction. (Josh Riegelhaupt)





From Baron Opportunity Fund first quarter 2016 commentary.







Check out Ron Baron latest stock trades

Baron Funds Comments on Alexion Pharmaceuticals - Feb 08, 2016

We also sold our Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) position in the third quarter to harvest a tax loss. We rebuilt our position this quarter. Alexion is the premier orphan disease company, whose lead product Soliris is a lifesaving medicine for both Paroxysmal Nocturnal Hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). The company has expanded its efforts in orphan diseases (particularly ones with high unmet needs) with the acquisition of Strensiq for Hypophosphatasia (HPP) and Kanuma for Lysosomal Acid Lipase Deficiency (LAL-D), both of which are approved or in the final stages of approval for launch worldwide.



From the Baron Funds Opportunity Fund fourth quarter 2015 commentary.



Check out Ron Baron latest stock trades

Baron Funds Comments on Alexion Pharmaceuticals Inc. - Nov 10, 2015

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) is the premier orphan disease company, whose lead product Soliris is a lifesaving medicine for both Paroxysmal Nocturnal Hemoglobinuria (PNH) and Atypical hemolytic uremic syndrome (aHUS). The company has expanded its efforts in orphan diseases (particularly ones with high unmet needs) with the acquisition of Strensiq for HPP (Hypophosphatasia) and Kanuma for LAL-D (Lysosomal Acid Lipase Deficiency), both of which are approved or in the final stages of approval for launch worldwide. The company recently announced the delay of Strensiq approval by the FDA for manufacturing related issues. With greater uncertainty surrounding the approval of Strensiq, and overall sentiment on the biotech industry souring, we reduced our exposure to the industry and sold our position in Alexion.





From the Baron Opportunity Fund third quarter 2015 letter.



Check out Ron Baron latest stock trades

Baron Funds Comments on Alexion Pharmaceuticals Inc. - Aug 19, 2015

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) is a biopharmaceutical company that pioneered the “orphan disease” space by focusing on delivering life-transforming treatments for patients with devastating (life threatening) and ultra-rare (or orphan) diseases. Alexion is a leader in disease education and diagnostic initiatives to ensure that patients for its drugs are rapidly and accurately diagnosed. We believe Alexion’s first commercial drug, known as Soliris, which is used to treat paroxysmal nocturnal hemoglobinuria (called PNH) and atypical hemolytic uremic syndrome (referred to as aHUS), continues to possess a large global growth opportunity. Alexion has a pipeline of additional rare-disease treatments, and recently acquired Synageva, a company with two additional drugs for treating rare and devastating metabolic diseases, as well as a pipeline of other compounds, giving the company what we believe to be the most robust rare disease pipeline in the biotech industry.





From Baron Funds’ second quarter 2015 commentary.



Check out Ron Baron latest stock trades

Top Ranked Articles about Alexion Pharmaceuticals Inc

Spiros Segalas on Alexion Pharmaceuticals Guru stock highlight
Many Health Care stocks that have been strong positive contributors to return over past quarters continued to face concerns about drug pricing. Biotechnology companies that sell innovative, high priced drugs lost ground, including Alexion Pharmaceuticals (NASDAQ:ALXN). We believe that the long-term fundamentals of the Fund’s biotechnology holdings remain intact, and that current valuations underestimate the potential of pipeline drugs.


From Spiros Segamas' Armiel Appreciation second quarter 2016 commentary. Read more...
Baron Funds Comments on Alexion Pharmaceuticals Guru stock highlight
Shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) fell in the first quarter as a result of the significant correction in the biotech/pharma space. Alexion develops treatments for rare diseases. Its high foreign exchange exposure and high Read more...
Baron Funds Comments on Alexion Pharmaceuticals Guru stock highlight
Shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) fell in the first quarter as a result of the significant correction in the biotech/pharma space. Alexion develops treatments for rare diseases. Its high foreign exchange exposure and high multiple also pressured the stock. Overall, we believe there have been no significant changes to the fundamentals of Alexion’s investment thesis (innovative, exceptionally well-managed company with unique assets and pricing power) and we retain conviction. Read more...
Baron Funds Comments on Alexion Pharmaceuticals Guru stock highlight
Shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) fell sharply in the first quarter as a result of the massive correction in the biotech/pharma space. Alexion develops treatments for rare diseases. Its high foreign exchange exposure and high multiple also pressured the stock. Overall, we believe there have been no significant changes to the fundamentals of Alexion’s story and we retain conviction. (Josh Riegelhaupt) Read more...
Baron Funds Comments on Alexion Pharmaceuticals Guru stock highlight
We also sold our Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) position in the third quarter to harvest a tax loss. We rebuilt our position this quarter. Alexion is the premier orphan disease company, whose lead product Soliris is a lifesaving medicine for both Paroxysmal Nocturnal Hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). The company has expanded its efforts in orphan diseases (particularly ones with high unmet needs) with the acquisition of Strensiq for Hypophosphatasia (HPP) and Kanuma for Lysosomal Acid Lipase Deficiency (LAL-D), both of which are approved or in the final stages of approval for launch worldwide. Read more...
Weekly CFO Sells Highlight: Tyson Foods, Alexion Pharmaceuticals, Gilead Sciences Recent insider sales from company CFOs
According to GuruFocus Insider Data, the recent CFO sales were: Tyson Foods Inc. (NYSE:TSN), Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) and Gilead Sciences Inc. (NASDAQ:GILD). Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 76.76
ALXN's P/E(ttm) is ranked lower than
80% of the 250 Companies
in the Global Biotechnology industry.

( Industry Median: 27.27 vs. ALXN: 76.76 )
Ranked among companies with meaningful P/E(ttm) only.
ALXN' s P/E(ttm) Range Over the Past 10 Years
Min: 13.83  Med: 78.42 Max: 961.82
Current: 76.76
13.83
961.82
Forward P/E 23.64
ALXN's Forward P/E is ranked lower than
62% of the 55 Companies
in the Global Biotechnology industry.

( Industry Median: 17.39 vs. ALXN: 23.64 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 76.76
ALXN's PE(NRI) is ranked lower than
79% of the 248 Companies
in the Global Biotechnology industry.

( Industry Median: 27.60 vs. ALXN: 76.76 )
Ranked among companies with meaningful PE(NRI) only.
ALXN' s PE(NRI) Range Over the Past 10 Years
Min: 13.71  Med: 77.68 Max: 705.33
Current: 76.76
13.71
705.33
Price/Owner Earnings (ttm) 73.41
ALXN's Price/Owner Earnings (ttm) is ranked lower than
72% of the 142 Companies
in the Global Biotechnology industry.

( Industry Median: 28.19 vs. ALXN: 73.41 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
ALXN' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 15.74  Med: 76.31 Max: 1108.89
Current: 73.41
15.74
1108.89
P/B 3.31
ALXN's P/B is ranked higher than
53% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: 3.50 vs. ALXN: 3.31 )
Ranked among companies with meaningful P/B only.
ALXN' s P/B Range Over the Past 10 Years
Min: 3  Med: 10.44 Max: 166.91
Current: 3.31
3
166.91
P/S 9.51
ALXN's P/S is ranked higher than
53% of the 695 Companies
in the Global Biotechnology industry.

( Industry Median: 10.41 vs. ALXN: 9.51 )
Ranked among companies with meaningful P/S only.
ALXN' s P/S Range Over the Past 10 Years
Min: 8.6  Med: 16.22 Max: 929.17
Current: 9.51
8.6
929.17
PFCF 71.72
ALXN's PFCF is ranked lower than
80% of the 123 Companies
in the Global Biotechnology industry.

( Industry Median: 24.25 vs. ALXN: 71.72 )
Ranked among companies with meaningful PFCF only.
ALXN' s PFCF Range Over the Past 10 Years
Min: 40  Med: 63.1 Max: 3326.67
Current: 71.72
40
3326.67
POCF 46.56
ALXN's POCF is ranked lower than
75% of the 186 Companies
in the Global Biotechnology industry.

( Industry Median: 19.60 vs. ALXN: 46.56 )
Ranked among companies with meaningful POCF only.
ALXN' s POCF Range Over the Past 10 Years
Min: 30.61  Med: 48.62 Max: 83.31
Current: 46.56
30.61
83.31
EV-to-EBIT 47.34
ALXN's EV-to-EBIT is ranked lower than
78% of the 252 Companies
in the Global Biotechnology industry.

( Industry Median: 19.98 vs. ALXN: 47.34 )
Ranked among companies with meaningful EV-to-EBIT only.
ALXN' s EV-to-EBIT Range Over the Past 10 Years
Min: -115.8  Med: 47 Max: 499.4
Current: 47.34
-115.8
499.4
EV-to-EBITDA 30.04
ALXN's EV-to-EBITDA is ranked lower than
67% of the 276 Companies
in the Global Biotechnology industry.

( Industry Median: 16.24 vs. ALXN: 30.04 )
Ranked among companies with meaningful EV-to-EBITDA only.
ALXN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -145  Med: 42.15 Max: 258.3
Current: 30.04
-145
258.3
PEG 2.12
ALXN's PEG is ranked lower than
51% of the 95 Companies
in the Global Biotechnology industry.

( Industry Median: 2.10 vs. ALXN: 2.12 )
Ranked among companies with meaningful PEG only.
ALXN' s PEG Range Over the Past 10 Years
Min: 0.68  Med: 1.61 Max: 11.71
Current: 2.12
0.68
11.71
Shiller P/E 119.16
ALXN's Shiller P/E is ranked lower than
81% of the 58 Companies
in the Global Biotechnology industry.

( Industry Median: 48.79 vs. ALXN: 119.16 )
Ranked among companies with meaningful Shiller P/E only.
ALXN' s Shiller P/E Range Over the Past 10 Years
Min: 107.19  Med: 276.04 Max: 1466
Current: 119.16
107.19
1466
Current Ratio 3.11
ALXN's Current Ratio is ranked lower than
62% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.22 vs. ALXN: 3.11 )
Ranked among companies with meaningful Current Ratio only.
ALXN' s Current Ratio Range Over the Past 10 Years
Min: 2.3  Med: 6.22 Max: 52.92
Current: 3.11
2.3
52.92
Quick Ratio 2.67
ALXN's Quick Ratio is ranked lower than
63% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.94 vs. ALXN: 2.67 )
Ranked among companies with meaningful Quick Ratio only.
ALXN' s Quick Ratio Range Over the Past 10 Years
Min: 2.03  Med: 6.02 Max: 52.92
Current: 2.67
2.03
52.92
Days Inventory 444.84
ALXN's Days Inventory is ranked lower than
93% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 128.70 vs. ALXN: 444.84 )
Ranked among companies with meaningful Days Inventory only.
ALXN' s Days Inventory Range Over the Past 10 Years
Min: 202.61  Med: 292.91 Max: 959.95
Current: 444.84
202.61
959.95
Days Sales Outstanding 83.63
ALXN's Days Sales Outstanding is ranked lower than
66% of the 601 Companies
in the Global Biotechnology industry.

( Industry Median: 61.72 vs. ALXN: 83.63 )
Ranked among companies with meaningful Days Sales Outstanding only.
ALXN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 70.74  Med: 106.12 Max: 339.23
Current: 83.63
70.74
339.23
Days Payable 42.59
ALXN's Days Payable is ranked lower than
60% of the 412 Companies
in the Global Biotechnology industry.

( Industry Median: 57.94 vs. ALXN: 42.59 )
Ranked among companies with meaningful Days Payable only.
ALXN' s Days Payable Range Over the Past 10 Years
Min: 42.59  Med: 90.78 Max: 494.52
Current: 42.59
42.59
494.52

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -5.00
ALXN's 3-Year Average Share Buyback Ratio is ranked higher than
72% of the 555 Companies
in the Global Biotechnology industry.

( Industry Median: -11.30 vs. ALXN: -5.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ALXN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -24.9  Med: -11.2 Max: -2.4
Current: -5
-24.9
-2.4

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 2.25
ALXN's Price/Projected FCF is ranked higher than
60% of the 159 Companies
in the Global Biotechnology industry.

( Industry Median: 2.84 vs. ALXN: 2.25 )
Ranked among companies with meaningful Price/Projected FCF only.
ALXN' s Price/Projected FCF Range Over the Past 10 Years
Min: 2.12  Med: 5.44 Max: 142.22
Current: 2.25
2.12
142.22
Price/Median PS Value 0.58
ALXN's Price/Median PS Value is ranked higher than
76% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: 0.93 vs. ALXN: 0.58 )
Ranked among companies with meaningful Price/Median PS Value only.
ALXN' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.38  Med: 1.23 Max: 53.16
Current: 0.58
0.38
53.16
Price/Peter Lynch Fair Value 3.05
ALXN's Price/Peter Lynch Fair Value is ranked lower than
67% of the 64 Companies
in the Global Biotechnology industry.

( Industry Median: 1.71 vs. ALXN: 3.05 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
ALXN' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.56  Med: 2.97 Max: 11.39
Current: 3.05
0.56
11.39
Earnings Yield (Greenblatt) (%) 2.14
ALXN's Earnings Yield (Greenblatt) (%) is ranked higher than
80% of the 942 Companies
in the Global Biotechnology industry.

( Industry Median: -8.50 vs. ALXN: 2.14 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ALXN' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.2  Med: 2 Max: 3
Current: 2.14
0.2
3
Forward Rate of Return (Yacktman) (%) 30.53
ALXN's Forward Rate of Return (Yacktman) (%) is ranked higher than
76% of the 119 Companies
in the Global Biotechnology industry.

( Industry Median: 15.80 vs. ALXN: 30.53 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
ALXN' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -18.5  Med: 0.5 Max: 75.6
Current: 30.53
-18.5
75.6

More Statistics

Revenue (TTM) (Mil) $2,954
EPS (TTM) $ 1.64
Beta1.15
Short Percentage of Float2.68%
52-Week Range $110.56 - 193.45
Shares Outstanding (Mil)224.25

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 3,091 3,555 4,443 5,403
EPS ($) 4.61 5.29 7.36 9.84
EPS w/o NRI ($) 4.61 5.29 7.36 9.84
EPS Growth Rate
(3Y to 5Y Estimate)
15.26%
Dividends Per Share ($)
» More Articles for ALXN

Headlines

Articles On GuruFocus.com
Spiros Segalas on Alexion Pharmaceuticals Aug 18 2016 
Spiros 'Sig' Segalas' Capital Appreciation Fund 2nd Quarter Commentary Nov 07 2016 
Frank Sands Sells Visa, Baidu, Alibaba May 24 2016 
Baron Funds Comments on Alexion Pharmaceuticals May 23 2016 
Baron Funds Comments on Alexion Pharmaceuticals May 23 2016 
Baron Funds Comments on Alexion Pharmaceuticals May 06 2016 
Baron Funds Comments on Alexion Pharmaceuticals Feb 08 2016 
Weekly CFO Sales Highlight: H&R Block, DISH Network, Alexion Pharmaceuticals Jan 03 2016 
Weekly CFO Sells Highlight: Tyson Foods, Alexion Pharmaceuticals, Gilead Sciences Dec 13 2015 
Weekly Insider Sells Highlights: CDW, Twitter, P&G, Alexion Pharmaceuticals Dec 10 2015 

More From Other Websites
INVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Alexion... Dec 05 2016
INVESTOR ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against... Dec 05 2016
Alexion Presents Data from Ultra-Rare Blood Disorder Study Dec 05 2016
2:22 am Alexion Pharma presents new data from ALXN1210 dose-escalation study; recruitment under way... Dec 05 2016
New Data from ALXN1210 Dose-Escalation Study Presented at ASH Show Rapid and Sustained Reductions in... Dec 04 2016
INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Alexion... Dec 02 2016
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in... Dec 02 2016
SHAREHOLDER NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Alexion... Dec 01 2016
Is Alexion Pharmaceuticals, Inc. (ALXN) a Good Stock To Buy? Dec 01 2016
Lifshitz & Miller Law Firm Announces Investigation of Alexion Pharmaceuticals, Inc., Blue Nile,... Dec 01 2016
ETFs with exposure to Alexion Pharmaceuticals, Inc. : December 1, 2016 Dec 01 2016
SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Alexion... Nov 30 2016
INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Alexion Pharmaceuticals, Inc. of a... Nov 30 2016
Alexion Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ALXN-US :... Nov 30 2016
U.S. Stocks Edge Higher, Led by Health-Care Gains Nov 30 2016
The Hot Stock: Alexion Pharmaceuticals Jumps 5.2% Nov 29 2016
Healthcare Stocks Help Nasdaq Reach New Heights Nov 29 2016
Stocks Subdued by Lower Commodities Prices Nov 29 2016
INVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Alexion... Nov 29 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)